Chapter/Section Purchase

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 PCR
1.2.3 In-situ Hybridization
1.2.4 Immunohistochemistry
1.2.5 Sequencing
1.2.6 Others
1.3 Market by Application
1.3.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Neurological Disorders
1.3.4 Cardiovascular Disease
1.3.5 Immunological Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Perspective (2017-2028)
2.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Growth Trends by Region
2.2.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Region (2017-2022)
2.2.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Region (2023-2028)
2.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Dynamics
2.3.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Trends
2.3.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
2.3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges
2.3.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players by Revenue
3.1.1 Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players by Revenue (2017-2022)
3.1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Players (2017-2022)
3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue
3.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue in 2021
3.5 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Key Players Head office and Area Served
3.6 Key Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Breakdown Data by Type
4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Type (2017-2022)
4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Type (2023-2028)
5 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Breakdown Data by Application
5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Application (2017-2022)
5.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2017-2028)
6.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type
6.2.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2017-2022)
6.2.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2023-2028)
6.2.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Type (2017-2028)
6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application
6.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2017-2022)
6.3.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2023-2028)
6.3.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Application (2017-2028)
6.4 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
6.4.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2017-2022)
6.4.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2017-2028)
7.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type
7.2.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2017-2022)
7.2.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2023-2028)
7.2.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Type (2017-2028)
7.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application
7.3.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2017-2022)
7.3.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2023-2028)
7.3.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Application (2017-2028)
7.4 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
7.4.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2017-2022)
7.4.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2017-2028)
8.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type
8.2.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Type (2017-2028)
8.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application
8.3.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Application (2017-2028)
8.4 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region
8.4.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2017-2028)
9.2 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type
9.2.1 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2017-2022)
9.2.2 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2023-2028)
9.2.3 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Type (2017-2028)
9.3 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application
9.3.1 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2017-2022)
9.3.2 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2023-2028)
9.3.3 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Application (2017-2028)
9.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
9.4.1 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2017-2022)
9.4.2 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2017-2028)
10.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type
10.2.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Type (2017-2028)
10.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application
10.3.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Application (2017-2028)
10.4 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
10.4.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Qiagen NV
11.1.1 Qiagen NV Company Details
11.1.2 Qiagen NV Business Overview
11.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.1.4 Qiagen NV Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2017-2022)
11.1.5 Qiagen NV Recent Developments
11.2 GE Healthcare
11.2.1 GE Healthcare Company Details
11.2.2 GE Healthcare Business Overview
11.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.2.4 GE Healthcare Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2017-2022)
11.2.5 GE Healthcare Recent Developments
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.3.4 Agilent Technologies Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2017-2022)
11.3.5 Agilent Technologies Recent Developments
11.4 F Hoffman La Roche
11.4.1 F Hoffman La Roche Company Details
11.4.2 F Hoffman La Roche Business Overview
11.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.4.4 F Hoffman La Roche Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2017-2022)
11.4.5 F Hoffman La Roche Recent Developments
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Details
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.5.4 Foundation Medicine Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2017-2022)
11.5.5 Foundation Medicine Recent Developments
11.6 Thermo Fisher Scientific Inc.
11.6.1 Thermo Fisher Scientific Inc. Company Details
11.6.2 Thermo Fisher Scientific Inc. Business Overview
11.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.6.4 Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2017-2022)
11.6.5 Thermo Fisher Scientific Inc. Recent Developments
11.7 Leica Biosystems Nussloch GmBH
11.7.1 Leica Biosystems Nussloch GmBH Company Details
11.7.2 Leica Biosystems Nussloch GmBH Business Overview
11.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.7.4 Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2017-2022)
11.7.5 Leica Biosystems Nussloch GmBH Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.8.4 Pfizer Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2017-2022)
11.8.5 Pfizer Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer